Saturday, July 11, 2026

Drug profile · INN

tolbutamide sodium

tolbutamide sodium (ORINASE DIAGNOSTIC) is a sulfonylurea receptor 1, kir6.2 blocker. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — tolbutamide sodium
US status
approved
Class
Route
INJECTION
Patents
0
Programs
0
Data quality
0.84

Quick answer

tolbutamide sodium (ORINASE DIAGNOSTIC) is a sulfonylurea receptor 1, kir6.2 blocker. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN tolbutamide sodium
Brand ORINASE DIAGNOSTIC
Mechanism Sulfonylurea receptor 1, Kir6.2 blocker
Target Sulfonylurea receptor 1, Kir6.2
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Sulfonylurea receptor 1, Kir6.2 blocker

Primary target: Sulfonylurea receptor 1, Kir6.2

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. acetohexamide Sulfonylurea receptor 1, Kir6.2 blocker
  2. chlorpropamide Sulfonylurea receptor 1, Kir6.2 blocker
  3. glimepiride Sulfonylurea receptor 1, Kir6.2 blocker
  4. glipizide Sulfonylurea receptor 1, Kir6.2 blocker
  5. glyburide Sulfonylurea receptor 1, Kir6.2 blocker
  6. nateglinide Alimentary tract and metabolism (A10)

Frequently asked questions

What is tolbutamide sodium?

tolbutamide sodium (ORINASE DIAGNOSTIC) is a sulfonylurea receptor 1, kir6.2 blocker. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for tolbutamide sodium?

ORINASE DIAGNOSTIC is a marketed brand name for tolbutamide sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of tolbutamide sodium?

tolbutamide sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.